Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects

European Journal of Endocrinology

Volumn 157, Issue 4, 2007, Pages 443-449

  Krusinova E ^a   Klementova M ^a   Kopecky J ^a   Wohl, P ^a   Kazdova L ^a   Mlejnek, P ^a   Pravenec, M ^b   Hill, M ^c   Pelikánová, Terezie ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; RESISTIN;

ABDOMINAL FAT; ACUTE DISEASE; ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; INSULIN SENSITIVITY; MALE; NEEDLE BIOPSY; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE;

ADIPONECTIN; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG COMBINATIONS; GENE EXPRESSION; GLUCOSE CLAMP TECHNIQUE; HEALTH; HUMANS; HYPERINSULINISM; INSULIN; INTRA-ABDOMINAL FAT; LOSARTAN; MALE; RECEPTOR, ANGIOTENSIN, TYPE 1; RESISTIN;

EID: 35548953802     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0034     Document Type: Article

References (46)

1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS & Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001 409 307-312.
2. Steppan CM & Lazar MA. The current biology of resistin. Journal of Internal Medicine 2004 255 439-447.
3. Yu YH & Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelac of insulin-resistant adipose tissue. Circulation Research 2005 96 1042-1052.
4. Arner P. Resistin: yet another adipokine tells us that men are not mice. Diabetologia 2005 48 2203-2205.
5. Kershaw EE & Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004 89 2548-2556.
6. Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A & Trischitta V. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. Journal of Clinical Endocrinology and Metabolism 2006 91 2792-2795.
7. Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, Harlan DM & Shalev A. Resistin is expressed in pancreatic islets. Biochemical and Biophysisical Research Communications 2003 310 641-645.
8. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K & Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Invesigation 2006 116 1784-1792.
9. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA & Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes, Obesity and Metabolism 2006 8 264-280.
10. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Letters 2006 580 2917-2921.
11. Berg AH & Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005 96 939-949.
12. Kurtz TW & Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Journal of Hypertension 2004 22 2253-2261.
13. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes & Metabolism 2004 30 498-505.
14. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K & Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. Journal of Hypertension 2004 22 1977-1982.
15. Sharma AM, Janke J, Gorzelniak K, Engeli S & Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002 40 609-611.
16. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK & Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001 38 884-890.
17. Wang CH, Leung N, Lapointe N, Szeto L, Uffelman KD, Giacca A, Rouleau JL & Lewis GF. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 2003 107 1923-1929.
18. Nielsen S, Hove KY, Dollerup J, Paulsen PL, Christiansen JS, Schmitz O & Mogensen CE. Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetes, Obesity and Metabolism 2001 3 463-471.
19. Fishman S, Rapoport MJ, Weissgarten J, Zaidenstein R, Dishi V, Hartzeanu I & Golik A. The effect of Losartan on insulin resistance and beta cell function in chronic hemodialysis patients. Renal Failure 2001 23 685-692.
20. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes and Metabolism 2004 30 487-496.
21. Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F & Ozata M. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. Journal of the Renin-Angiotensin-Aldosterone System 2001 2 112-116.
22. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D & Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003 42 76-81.
23. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH. Ahn TH, Choi IS & Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004 110 3687-3692.
24. Pelikanova T, Smrckova i, Krizova J, Stribrna J & Lanska V. Effects of insulin and lipid emulsion on renal haemodynamics and renal sodium handling in IDDM patients. Diabetologia 1996 39 1074-1082.
25. Goodall I. HbAlc standardisation destination-global IFCC Standardisation. How, why, where and when-a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes. Clinical Biochemist. Reviews 2005 26 5-19.
26. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH & Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Journal of Clinical Endocrinology and Metabolism 2003 88 6098-6106.
27. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E & Smith SR. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. Journal of Clinical Endocrinology and Metabolism 2004 89 1844-1848.
28. Westerbacka J, Corner A, Kannisto K, Kolak M, Makkonen J, Korsheninnikova E, Nyman T, Hamsten A, Fisher RM & Yki-Jarvinen H. Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects. Diabetologia 2006 49 132-140.
29. Hojlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JF & Beck-Nielsen H. Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006 49 1283-1291.
30. Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF & Spranger J. Insulin decreases human adiponectin plasma levels. Hormone and Metabolic Research 2002 34 655-658.
31. Brame LA, Considine RV, Yamauchi M, Baron AD & Mather KJ. Insulin and endothelin in the acute regulation of adiponectin in vivo in humans. Obesity Research 2005 13 582-588.
32. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M & Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002 51 2968-2974.
33. Koistinen HA, Remitz A, Koivisto VA & Ebeling P. Paradoxical rise in serum adiponectin concentration in the face of acid-induced insulin resistance 13-cis-retinoic. Diabetologia 2006 49 383-386.
34. Dullaart RP, Riemens SC, Meinardi JR, Wolffenbuttel BH & Sluiter WJ. Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox. Scandinavian Journal of Clinical and Laboratory Investigation 2005 65 523-531.
35. Heliovaara W Strandberg TE, Karonen SL & Ebeling P. Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Hormone and Metabolic Research 2006 38 336-340.
36. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE & Kumar S. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 2005 48 1084-1087.
37. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y & Brichard SM. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochemical and Biophysisical Research Communications 2001 288 1102-1107.
38. Fasshauer M, Klein J, Neumann S, Eszlinger M & Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochemical and Biophysisical Research Communications 2002 290 1084-1089.
39. Fain IN, Madan AK, Hiler ML, Cheema P & Bahouth SW Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004 145 2273-2282.
40. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T & Kintscher U. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006 47 586-589.
41. Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualdiero P, Varricchio G, Verza M & Varricchio M. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. Journal of Human Hypertension 1997 11 307-312.
42. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G & Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. American Journal of Hypertension 2001 14 921-926.
43. Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, Deyneli O, Haklar G & Akalin S. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. Journal of the Renin-Angiotensin-Aldosterone System 2003 4 197-203.
44. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thone-Reineke C, Unger T & Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005 46 137-143.
45. Zorad S, Don JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J & Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. European Journal of Pharmacology 2006 552 112-122.
46. Ramracheya RD, Muller DS, Wu Y, Whitehouse BJ, Huang GC, Amiel SA, Karalliedde J, Viberti G, Jones PM & Persaud SJ. Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 2006 49 321-331.